Epcoritamab plus R-CHOP reduced the risk of progression or death by 51% vs R-CHOP alone in newly diagnosed DLBCL.
|Videos|March 1, 2019
Dr. Daver Discusses Use of MRD Assessment in Hematologic Malignancies
Author(s)Naval G. Daver, MD
Naval G. Daver, MD, discusses the role of minimal residual disease assessment in the treatment of patients with hematologic malignancies.
Advertisement
Naval G. Daver, MD, oncologist, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the role of minimal residual disease (MRD) assessment in the treatment of patients with hematologic malignancies. Daver says MRD has emerged as an important part of predicting outcomes in these patients compared to previous standards in this setting.
Advertisement
Related to this article
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
Oral azacitidine and cedazuridine met the end point of total cycle azacitidine exposure vs subcutaneous azacitidine in MDS or CMML.
Interim data showed that the BCMA-directed CAR T-cell therapy NXC-201 generated complete responses in relapsed/refractory AL amyloidosis.
Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.
The third BLA submission for tabelecleucel follows 2 CRLs and includes updated ALLELE data with additional patients and longer follow-up.
Advertisement
Advertisement
Trending on OncLive
1
Epcoritamab Plus R-CHOP Meets PFS End Point in Newly Diagnosed DLBCL
2
‘Our Impact Will Be Broad and Transformative’: Wells Messersmith, MD, Takes the Reins at CU Anschutz Cancer Center
3
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
4
Berzosertib Plus Carboplatin Fails to Improve Responses in Pretreated mCRPC
5